About Astria Therapeutics
Astria Therapeutics is a publicly listed company based in Boston (United States) founded in 2008 by Jill Milne, and was acquired by BioCryst in October 2025. Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed. It operates on a HealthTech model. Astria Therapeutics has raised $196.54 million across 15 funding rounds from investors including BioCryst, HHS and Perceptive Advisors. The company has 78 employees. Astria Therapeutics has completed 1 acquisition, including Quellis Biosciences. Its chief executive, as recorded, is Jill Milne. Astria Therapeutics offers products and services including Navenibart (STAR-0215) and STAR-0310. Its focus areas include Biotechnology and Immunologic Therapies. Its legal entity is Astria Therapeutics, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Astria Therapeutics is engaged in the development of life-changing therapies for patients and families affected by allergic and immunologic diseases. The company is dedicated to addressing unmet needs in therapeutic areas such as Hereditary Angioedema and Atopic Dermatitis. Solutions like Navenibart (STAR-0215) and STAR-0310 are being developed through clinical trials to provide innovative treatment options. The organization is guided by patient stories and community feedback to shape its scientific and therapeutic advancements. Sectors of focus include biotechnology and healthcare, with an emphasis on transparency and trust-building with stakeholders.
Products & Services of Astria Therapeutics
Astria Therapeutics offers a comprehensive portfolio of products and services, including Navenibart (STAR-0215) and STAR-0310.
Developed for treating Hereditary Angioedema in patients.
Designed for managing Atopic Dermatitis in patients.
Funding Insights of Astria Therapeutics
Astria Therapeutics has successfully raised a total of $196.54M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $110.01 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $196.54M
- Total Rounds 15
- Last Round Post-IPO — $110.01M
- First Round $925,000
(Feb 2009)
- Investors Count 4
Latest 10 of 15 funding rounds of Astria Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $110.01M | Post-IPO | – | – | |
| Mar 2015 | $12.41M | Series B | – | – | – |
| Nov 2013 | $32.43M | Series B | – | – | |
| Nov 2013 | $32.4M | Series B | – | – | |
| Jun 2013 | $9.2M | Series B | – | – | – |
| Feb 2013 | $9M | Series B | – | – | |
| Apr 2012 | $120,000 | Grant | – | – | – |
| Dec 2011 | $8M | Series A | – | – | |
| Dec 2010 | $14.5M | Series A | – | – | – |
| Sep 2010 | $179,900 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Astria Therapeutics
Astria Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include BioCryst, HHS and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital fund and fund of funds focused on the life science sector | lightstonevc.com | Menlo Park, United States | ||
| medimmuneventures.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of small molecule drugs for orphan & autoimmune diseases and antivirals | 1986 | biocryst.com | Durham, United States |
Investor details for Astria Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Astria Therapeutics
69 people are tracked at Astria Therapeutics (46 in leadership, 7 in board & advisors, 16 in team); the tracked headcount is 78.
| Name | Role | Group |
|---|---|---|
Jill Milne | Founder & CEO | Leadership |
Ben Harshbarger | Senior Vice President, General Counsel | Leadership |
Jill C. Milne | Co-Founder & CEO | Leadership |
Andrew A. Komjathy | Chief Commercial Officer | Leadership |
Brendan Hanna | Vice President of IT & Facilities | Leadership |
Doris Le | Associate Director, Operations And Project Management | Leadership |
Kusumam Joseph | Senior Director Medical Affairs | Leadership |
Kiel Iwanik | Associate Director Business Development | Leadership |
Amanda Quigley | Associate Director, Drug Substance | Leadership |
Rafif Dagher | Executive Director | Leadership |
Harison C. Hong | Executive Director, Brand Lead - Navenibart | Leadership |
Stephanie Nowack | Director, Corporate Counsel | Leadership |
Yan Chen, PhD | VP, Program Lead | Leadership |
Howard Parker | Senior Director, Clinical Operations (snr Consultant) | Leadership |
Michele Gunsior | Executive Director | Leadership |
Noah Clauser | Chief Financial Officer | Leadership |
John Faherty | Associate Director | Leadership |
Bruce Szczepankiewicz | Director of Development Chemistry | Leadership |
Kristine Bernard | Vice President, Head of Clinical Operations | Leadership |
Omayra Rosenthal, PHR, SHRM-CP | Director, Human Resources | Leadership |
49 more people are available in the full profile.
Complete people profiles for Astria Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Astria Therapeutics
Astria Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ATXS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jun 2015
- Listed onNASDAQ: CATB
- Listed entityAstria Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS04635X1028
- Share price$12.58 (+0.64% on the day) · 2026-01-25
- Market capitalisation$718.1M
- EPS (diluted, trailing year)$-2.15
- Volume (last session)3,199,309
- Analyst consensusNeutral
Financials of Astria Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$94.3M | -$111.6M | |
| 2023 | -$72.9M | -$67.8M | |
| 2022 | -$51.8M | -$53.5M | |
| 2021 | -$194.9M | -$30.4M | |
| 2020 | -$37.3M | -$37.4M |
Detailed financial statements for Astria Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Astria Therapeutics
Astria Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Quellis Biosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-based therapeutics for rare diseases are developed and optimized. | quellisbio.com | Boston, United States | 2017 | Jan 2021 | •••• |
Complete acquisition details for Astria Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Astria Therapeutics
6 dated milestones of Astria Therapeutics across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Astria Therapeutics is founded.
- Funding First funding round of $925K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $110.0M.
- Acquisition Acquires Quellis Biosciences.
- Exit Acquired by BioCryst.
Competitors of Astria Therapeutics
Astria Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Astria Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Astria Therapeutics
The website of Astria Therapeutics (astriatx.com) receives about 6.6K visits a month.
- Monthly visits6.6K
▼ 8.8% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Astria Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Astria Therapeutics
Complete news archive for Astria Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Astria Therapeutics
Astria Therapeutics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Astria Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jill Milne is the CEO of Astria Therapeutics, as recorded in our data. They have also founded this company.
Astria Therapeutics is a funded company, having raised a total of $196.54M across 15 funding rounds to date. The company's 1st funding round was a Grant of $179.9K, raised on Feb 2009.
Astria Therapeutics has 78 employees.
Astria Therapeutics is engaged in the development of life-changing therapies for patients and families affected by allergic and immunologic diseases. The company is dedicated to addressing unmet needs in therapeutic areas such as Hereditary Angioedema and Atopic Dermatitis. Solutions like Navenibart (STAR-0215) and STAR-0310 are being developed through clinical trials to provide innovative treatment options. The organization is guided by patient stories and community feedback to shape its scientific and therapeutic advancements. Sectors of focus include biotechnology and healthcare, with an emphasis on transparency and trust-building with stakeholders.
Astria Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Astria Therapeutics offers Navenibart (STAR-0215) and STAR-0310.
Yes, Astria Therapeutics is publicly traded on NASDAQ under the ticker symbol ATXS.
Astria Therapeutics has made 1 acquisition, including Quellis Biosciences.
Astria Therapeutics has 5 investors. Key investors include BioCryst, HHS, Perceptive Advisors, Lightstone Ventures, and MedImmune Ventures.
Astria Therapeutics operates through Astria Therapeutics, Inc..